GlassScriptPhysician profile
Patrick Gibbons
NPI 1619282233
$7,543.95
in general payments reported to CMS, 2019-2025
13 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2021: $22.40 · 2022: $228 · 2023: $171 · 2024: $6,186 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,720 · Travel and Lodging: $1,218 · Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,720.00 |
| Travel and Lodging | $1,217.52 |
| Food and Beverage | $646.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,349.66 | 2019-2025 | |
| Viiv Healthcare Company | $406.43 | 2019-2024 | Dovato |
| Janssen Biotech, INC. | $368.63 | 2019 | |
| Abbvie INC. | $96.00 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $85.64 | 2019-2021 | |
| Novo Nordisk INC | $47.67 | 2022 | |
| Theratechnologies INC. | $45.04 | 2023 | Trogarzo, Egrifta |
| Janssen Scientific Affairs, LLC | $43.12 | 2019 | |
| Glaxosmithkline, LLC. | $31.10 | 2023-2024 | Pediarix, Bexsero, Rotarix |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $23.27 | 2023 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $12.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.